Two Tests May Be Better Than One at Predicting Survival
The two most common measures used in amyotrophic lateral sclerosis (ALS) assessments — the ALS functional rating scale-revised (ALSFRS-R)…
Articles by Forest Ray PhD
Arthritis Treatment Eases Signs of Inflammation in ALS Patients in Trial
Actemra (tocilizumab), an approved treatment for rheumatoid arthritis, was found to be safe and well-tolerated, and to reduce a key…
Luker Courage Award to Honor ‘Tenacious Spirit’ of ALS Community
Mitsubishi Tanabe Pharma America (MTPA) and Target ALS welcome nominations for the Target ALS Rebecca Luker Courage Award,…
Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing
Dosing has begun in a clinical trial of WVE-004, Wave Life Sciences‘ investigational therapy for amyotrophic lateral sclerosis…
Eli Lilly, Verge Partner to Identify and Test Potential ALS Therapies
Verge Genomics and Eli Lilly have entered into a three-year collaboration to find and develop therapies for amyotrophic lateral…
Orphan Drug Status Recommended for Pridopidine in Europe
A branch of the European Medicines Agency (EMA) has recommended that Prilenia’s investigational therapy pridopidine be designated an orphan medicine…
Exservan, Riluzole as Oral Film, Soon Available in US via PANTHERx
Note: This story was updated June 30, 2021, to clarify that Exservan is placed on top of the tongue, not…
Partnership Targets Gene-editing Therapies for Familial ALS
CRISPR Therapeutics and Capsida Biotherapeutics have partnered to develop gene-editing therapies for familial amyotrophic lateral sclerosis (ALS)…
$1M DOD Grant Supports AS-202 for Sporadic ALS
AcuraStem has been awarded a $1 million grant from the U.S. Department of Defense (DOD) to advance AS-202, a…
Studies Involving Masitinib Suspended
AB Science will suspend recruitment and treatment in all studies involving masitinib, a tyrosine kinase inhibitor being investigated…